Joel Greenblatt’s Akebia Therapeutics AKBA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-36,053
Closed -$41.1K – 1867
2026
Q2
$41.1K Buy
36,053
+8,881
+33% +$10.6K ﹤0.01% 1784
2026
Q1
$37.8K Buy
27,172
+11,202
+70% +$15.4K ﹤0.01% 1742
2025
Q4
$25.7K Buy
15,970
+1,471
+10% +$3.08K ﹤0.01% 1718
2025
Q3
$39.6K Sell
14,499
-1,070
-7% -$3.56K ﹤0.01% 1669
2025
Q2
$56.7K Buy
+15,569
New +$42.8K ﹤0.01% 1640
2021
Q3
– Sell
-19,195
Closed -$73K – 1013
2021
Q2
$73K Buy
+19,195
New +$64.6K ﹤0.01% 979

Other funds holding AKBA

Joel Greenblatt's AKBA Position: Q3 2026 in Review

Joel Greenblatt sold out of Akebia Therapeutics (AKBA) in Q3 2026, closing a stake of 36,053 shares — an estimated $41.1K sold.

Joel Greenblatt first reported a position in AKBA in Q2 2021 and held it in 6 quarters. The position peaked at $73K in Q2 2021. 157 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • Joel Greenblatt reported no remaining Akebia Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Joel Greenblatt sold 36,053 Akebia Therapeutics shares in Q3 2026, an estimated $41.1K.
  • Joel Greenblatt first reported a position in Akebia Therapeutics in Q2 2021 and held it in 6 quarters.
  • Joel Greenblatt's Akebia Therapeutics position peaked at $73K in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.